细胞因子诱导激活的杀伤细胞联合化疗治疗晚期结直肠癌的临床观察

 目的 评价细胞因子诱导的杀伤细胞（CIK）联合化疗治疗晚期大肠癌的临床疗效。方法 取外周血50 ml，分离单个核细胞，体外经IL-2、IFN-γ、抗CD3单抗、IL-1刺激培养8天后获得CIK细胞。CIK联合化疗组、行单纯化疗的同期配对晚期大肠癌组患者各50例，比较近期疗效及生存率，流式细胞术检测回输CIK前后患者免疫学指标，并观察其生活质量改善情况及不良反应。结果 CIK细胞治疗前患者外周血中CD3+、CD4+、CD8+和NK细胞比例分别为54.779±14.228%、30.821±11.554%、16.676±6.256%、18.705±9.347%，治疗后分别为65.236±14.901%、37.292±8.880%、25.229±6.711%、22.950±8.9323%，较治疗前均显著提高(P<0.05)；CIK联合化疗组患者生活质量明显改善，不良反应轻微；CIK联合化疗组的疾病控制率(DCR)率为64%（32/50）高于单纯化疗组的40%（20/50）(P<0.05)，CIK联合化疗组与单纯化疗组生存率差异无统计学意义（P＞0.05）。结论 CIK联合化疗可增强晚期大肠癌患者免疫功能，提高患者生活质量，有较好的临床疗效。

Clinical observation of cytokine-induced killer cells combined with chemotherapy on the treatment of advanced colorectal cancer

Objective To evaluate the clinical effects of cytokine-induced killer （CIK） ceils combined with chemotherapy on the treatment of patients with advanced colorectal cancer. Methods CIK cells were prepared from 50 ml peripheral blood mononuclear ceils by stimulated with IL-2, IFN-γ anti-CD3 monoclone antibody, IL-1 for 8 d. The clinical effects and survival rate were compared between CIK cells combined with chemotherapy group and the chemotherapy group （50 patients with advanced colorectal cancer for each）. T cells and NK cells of patients were tested by FCM before and after CIK cells treatment. The improvement of quality of life and toxicity of this therapy were observed. Results The percentages of CD3＋, CD4＋, CD8＋ T cells and NK cells were （54.779±14.228） %, （30.821±11.554） %, （16.676±6.256） %, （18.705±9.347） % before CIK cells transfusion. After transfusion, the percentages were （65.236±14.901） %, （37.292±8.880） %, （25.229± 6.711） %, （22.950±8.933） %, respectively. The percentages were expanded greatly （P 〈 0.05）. The patients quality of life were improved clearly with lower toxicity. The DCR of CIK cells combined with chemotherapy group （64 %, 32/50） was higher than the chemotherapy group （40 %, 20/50） （P 〈 0.05）. The survival rate between two groups had no statistical significance （P 〉 0.05）. Conclusion Administration of CIK cells combined with chemotherapy can enhance immune function in patients with advanced colorectal cancer and improve their quality of life, and get good clinical efficacy.